The FLASH Study: A Study of Roflumilast Versus Placebo in Patients With Asthma (BY217/M2-023) - Full Text View

The FLASH Study: A Study of Roflumilast Versus Placebo in Patients With Asthma (BY217/M2-023)

This study has been completed.

Sponsored by:	ALTANA Pharma
Information provided by:	ALTANA Pharma
ClinicalTrials.gov Identifier:	NCT00076076

Purpose

The purpose of this study is to confirm the dose of roflumilast to be used for asthma management by comparing the effects of 250 mcg and 500 mcg oral roflumilast with placebo on pulmonary function and asthma symptoms.

Condition	Intervention	Phase
Asthma	Drug: Roflumilast	Phase III

MedlinePlus related topics:

Asthma

ChemIDplus related topics:

Roflumilast

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment

Official Title:	The FLASH Study: A Randomized, Controlled Study of Roflumilast 250 Mcg and 500 Mcg Versus Placebo in Patients With Asthma

Further study details as provided by ALTANA Pharma:

Primary Outcome Measures:

change in lung function.

Secondary Outcome Measures:

change in morning PEF
asthma symptom score
rescue medication
time to withdrawal due to worsening asthma.

Estimated Enrollment:	822
Study Start Date:	December 2003

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Main Inclusion Criteria:

Diagnosis of persistent chronic bronchial asthma
Baseline lung function within specified parameters
No change in asthma treatment during the last 4 weeks prior to start of baseline period
Stable clinical state
Except for asthma, in good health
Non-smokers or ex-smokers

Main Exclusion Criteria:

Poorly controlled asthma
Diagnosis of chronic pulmonary disease and/or other relevant lung diseases
Patients using continuously (more than 3 days per week) > 8 puffs/day rescue medication

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00076076

Show 41 Study Locations

Sponsors and Collaborators

ALTANA Pharma

Investigators


Principal Investigator:	Eli O. Meltzer, MD	Allergy & Asthma Medical Group & Research Center, San Diego, Ca 92123, USA

More Information

Study ID Numbers:	BY217/M2-023
First Received:	January 13, 2004
Last Updated:	December 15, 2006
ClinicalTrials.gov Identifier:	NCT00076076
Health Authority:	United States: Food and Drug Administration

Keywords provided by ALTANA Pharma:

Roflumilast

Asthma

Study placed in the following topic categories:

Hypersensitivity

Lung Diseases, Obstructive

Respiratory Tract Diseases

Lung Diseases

Hypersensitivity, Immediate

Asthma

Respiratory Hypersensitivity

Additional relevant MeSH terms:

Immune System Diseases

Bronchial Diseases

ClinicalTrials.gov processed this record on September 05, 2008